Related Experiment Video
Updated: Jul 14, 2025

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
Published on: May 30, 2025
A provisional evaluation of Australia's medical cannabis program
Myfanwy Graham1, Vivian Chiu2, Daniel Stjepanović2
1Centre for Drug Repurposing & Medicines Research, School of Medicine and Public Health, The University of Newcastle, Australia; Schaeffer Center for Health Policy & Economics, The University of Southern California, United States.
Abstract:
In 2016, the Australian Government legislated to allow cannabis to be prescribed to patients as an unapproved medicine under the special access provisions of the Therapeutic Goods Act. This paper compares the Australian regulatory approach with other national approaches, outlines the main provisions of the Special Access Scheme for medical cannabis, describes how the program has evolved since 2017, includes an analysis of adverse events reported to the Therapeutic Goods Administration, and discusses the barriers that remain for patients who wish to access medical cannabis. It assesses how well the Australian program has addressed the challenges of providing patients with easier access to medical cannabis while ensuring that high-quality products are used safely and effectively under medical guidance.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drug Regulation
Factors Affecting Drug Response: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials: Overview

